Apolipoprotein L1: from obscurity to consistency to controversy | Zendy

Michael S. Lipkowitz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Apolipoprotein L1: from obscurity to consistency to controversy

Author(s) -

Michael S. Lipkowitz

Publication year - 2014

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2014.319

Subject(s) - kidney disease , context (archaeology) , medicine , incidence (geometry) , disease , apolipoprotein b , endocrinology , pathology , intensive care medicine , biology , cholesterol , paleontology , physics , optics

Apolipoprotein L1 (APOL1) is associated with increased incidence of chronic kidney disease (CKD) and end-stage renal disease, and with faster progression of CKD, in African Americans. APOL1 is expressed in intra- and extrarenal vascular tissue, making it a candidate to explain the increased incidence of cardiovascular disease in CKD. This Commentary discusses the disparate results from three studies showing that APOL1 renal risk genotypes are either harmful, neutral, or protective in the context of cardiovascular disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research